BioSpace News Archive

Dante Genomics, a global leader in genomics and precision medicine, announced that the Company has begun using needleless, at-home blood collection kits for its premium clinical whole genome sequencing test, thus bringing the high quality of concierge clinics to at home testing.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced that members of the management team will participate in the following upcoming investor conferences.

Ocean Biomedical and Aesther Healthcare Acquisition Corp. announced the discovery of bispecific antibodies that target Chitinase 3-like-1 and immune checkpoint inhibitors, killing glioblastoma cells and melanoma cells, and blocking the metastasis of malignant melanoma cells to the lung by over 90%.

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12 through September 14, 2022.

Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of Master Key therapies, announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the H.C. Wainwright 24th Annual Global Investment Conference.

Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate virtually in the hybrid in-person and virtual H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022.

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 24th Global Investment Conference.

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, announced that the Company will participate in two upcoming investor conferences in September.

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need, announced that members of management will present at two upcoming investor conferences.

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer of VYNE, is scheduled to participate at the H.C. Wainwright 24th Annual Global Investment Conference (Hybrid) on September 13, 2022.